Brandon Beckendorf, formerly of OsteoMed and Arthrex, Inc., is the new Director of Engineering at Shelton, Connecticut-based Orchid Design. Beckendorf will oversee the development of orthopedic and spine products for Orchid’s customers.
Beckendorf New Engineering Director at Orchid Design

As the company writes in its July 25, 2017 news release, “Brandon comes to Orchid with strong product development experience in extremities, craniomaxillofacial, and sports medicine. Most recently, as the Director of Engineering at OsteoMed, he introduced lean product development, DFx, concurrent engineering, and a disciplined approach to project management to increase overall project performance. In his roles at both OsteoMed and Arthrex, Brandon developed a strong understanding of FDA regulations and product development know-how required for the global development of orthopedic implants and instruments. Brandon earned a ME and BS in Biomedical Engineering from Texas A&M University.”
“We are pleased to have Brandon join our team to continue to build on our 14 years of helping our customers launch innovative new products to help surgeons and their patients. His demonstrated leadership and product development expertise will expand our capabilities to drive new products to market for our customers,” Steve Maguire, General Manager, Orchid Design.
Beckendorf told OTW, “My first steps are to continue building a strong team with streamlined processes and look for ways to increase our value proposition to our customers.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.